Drug intelligence / Profile preview

THEO-741

Development stage: Preclinical
Lead developer: Theolytics
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

THEO-741 is an engineered oncolytic adenovirus candidate being developed by Theolytics for the treatment of colorectal cancer. Discovered through the company's proprietary ADENOVO platform—which utilizes phenotypic screening and Darwinian selection to identify optimal viral variants—THEO-741 is designed to selectively infect and lyse cancer cells while sparing healthy tissue. The candidate is further engineered with arming capabilities to enhance its immunotherapeutic potential by stimulating a systemic anti-tumor immune response. It is currently in preclinical development and represents a distinct pipeline program from the company's lead candidate, THEO-260.

Beyond the preview

Go deeper on THEO-741.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on THEO-741.

Explore the full profile